Open AccessElevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis
Author(s) -
Shikha Shrivastava,
Eric G. Meissner,
Emily K. Funk,
Seerat Poonia,
Virender Shokeen,
Thakur Arun,
Bhawna Poonia,
Shiv Kumar Sarin,
Nirupma Trehanpati,
Shyamasundaran Kottilil
Publication year - 2016
Publication title -
hepatology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.304
H-Index - 45
eISSN - 1936-0541
pISSN - 1936-0533
DOI - 10.1007/s12072-016-9733-6
Subject(s) - steatohepatitis , steatosis , isg15 , interferon , interferon stimulated gene , fatty liver , biology , irf5 , immunology , hepatitis c virus , lipid metabolism , medicine , innate immune system , endocrinology , virus , interferon regulatory factors , gene , immune system , genetics , disease , ubiquitin
HCV GT-3 has a more pronounced effect on hepatic steatosis and host lipids than other HCV genotypes and is proving less responsive to all oral interferon-free treatment with direct acting antiviral agents. As both HCV GT3 infection and NASH can result in steatosis and cirrhosis, we asked whether hepatic transcriptional profiles reflective of the host response to inflammation differed based on the etiology of injury.